13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001389933
Total reported value
$524.4M
$524.4M
83 檔
25.1%
During the Q2 2024 filing period, DAFNA Capital Management LLC (CIK: 0001389933) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $524.4M across 83 reported positions.
During Q2 2024, DAFNA Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.86% | -3.32% | +3.20% | |
| 2 | STXS | Stereotaxis Inc | Stock-Other | 5.95% | -1.24% | — | |
| 3 | ✓ | Merus N V | Stock-Other | 5.79% | — | +8.03% | |
| 4 | CYTK | Cytokinetics Inc | Stock-Healthcare | 5.15% | -0.47% | — | |
| 5 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 4.75% | +7.24% | — | |
| 6 | IDYA | Ideaya Biosciences Inc | Stock-Other | 3.54% | -0.08% | -5.41% | |
| 7 | ATRC | Atricure Inc | Stock-Other | 3.48% | -0.69% | +135.83% | |
| 8 | IBB | Ishares Biotechnology ETF | ETF-Tech | 3.36% | -0.85% | — | |
| 9 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.22% | +0.24% | -0.38% | |
| 10 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.70% | — | -1.87% | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 2.64% | -1.21% | EXIT | |
| 12 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.55% | -0.43% | — | |
| 13 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.40% | — | -2.58% | |
| 14 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.36% | -0.26% | — | |
| 15 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.27% | -1.22% | EXIT | |
| 16 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 2.19% | -4.77% | EXIT | |
| 17 | KURA | Kura Oncology Inc | Stock-Other | 2.08% | -0.19% | +2.63% | |
| 18 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.97% | -0.53% | -20.91% | |
| 19 | MORFUSD | Morphic Holding Inc | Stock-Other | 1.89% | — | — | |
| 20 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.88% | — | — | |
| 21 | BHVN | Biohaven Ltd. | Stock-Other | 1.81% | -1.24% | +84.22% | |
| 22 | DXCM | Dexcom Inc | Stock-Healthcare | 1.78% | -0.12% | — | |
| 23 | AXGN | Axogen Inc | Stock-Other | 1.62% | -0.04% | — | |
| 24 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.25% | +0.96% | -5.23% | |
| 25 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.11% | -0.91% | -2.50% | |
| 26 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | Bond | 1.06% | -1.35% | EXIT | |
| 27 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.04% | -0.17% | -0.70% | |
| 28 | IPSC | Century Therapeutics Inc | Stock-Other | 1.04% | -0.13% | +30.35% | |
| 29 | ALEC | Alector Inc | Stock-Other | 0.99% | -0.09% | — | |
| 30 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.97% | — | -12.74% | |
| 31 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.92% | +0.42% | +9.28% | |
| 32 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.77% | -0.15% | — | |
| 33 | PODD | Insulet CORP | Stock-Healthcare | 0.77% | +1.28% | — | |
| 34 | KROS | Keros Therapeutics Inc | Stock-Other | 0.74% | — | — | |
| 35 | ✓ | Acelyrin Inc | Stock-Other | 0.73% | — | +242.38% | |
| 36 | ALKS | Alkermes plc | Stock-Healthcare | 0.69% | -0.11% | — | |
| 37 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.67% | -0.15% | +43.05% | |
| 38 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.60% | — | +22.80% | |
| 39 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.59% | -0.02% | — | |
| 40 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.55% | — | — | |
| 41 | ARAY | Accuray Inc | Stock-Other | 0.53% | -0.07% | — | |
| 42 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.51% | — | +46.47% | |
| 43 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.49% | — | — | |
| 44 | ✓ | Mediwound LTD | Stock-Other | 0.46% | -0.09% | -34.05% | |
| 45 | BWAY | Brainsway Ltd-adr | Stock-Other | 0.43% | — | — | |
| 46 | INGN | Inogen Inc | Stock-Other | 0.41% | -0.15% | — | |
| 47 | ✓ | Immatics NV | Stock-Other | 0.40% | -0.28% | — | |
| 48 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.38% | — | -16.38% | |
| 49 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.36% | -0.04% | — | |
| 50 | CMPS | Compass Pathways PLC | Stock-Other | 0.35% | +2.39% | — |
According to official SEC Form 13F filings, DAFNA Capital Management LLC reported a total U.S. public equity portfolio value of $524.4M across 83 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, STXS, MERUS N V) accounted for 25.1% of total reported equity market value during Q2 2024.
During Q2 2024, DAFNA Capital Management LLC's top holdings by market value included XBI (9.9%)、STXS (6.0%)、MERUS N V (5.8%). The largest single position, XBI, represented 9.9% of total portfolio value.
In Q2 2024, DAFNA Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.